Resource Type

Article

Year

2019

Disorder / CDG Type

All CDGs

Abstract

The amount of data collected and managed in (bio)medicine is ever-increasing. Thus, there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases (RDs), which are severely underrepresented in basic and clinical research, can particularly benefit from AI technologies. Of the more than 7000 RDs described worldwide, only 5% have a treatment. The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics, patient registries, and so on) can be used to overcome RDs' challenges (e.g., low diagnostic rates, reduced number of patients, geographical dispersion, and so on). Ultimately, RDs' AI-mediated knowledge could significantly boost therapy development. Presently, there are AI approaches being used in RDs and this review aims to collect and summarize these advances. A section dedicated to congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a potential study model for other common diseases and RDs, has also been included.

Authors

Sandra Brasil
Carlota Pascoal
Rita Francisco
Vanessa Dos Reis Ferreira
Paula A Videira
Gonçalo Valadão

Keywords

Artificial Intelligence
Big Data
Congenital Disorders of Glycosylation
Diagnosis
Drug Repurposing
Machine Learning
Personalized Medicine
Rare Diseases

View or Download

To view or download this resource you are required to be logged in.

If you have an account please Login here. If not, you can create one here.


Page modified at Thursday, February 10, 2022 - 15:50